{"id":"me-609","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ME-609 targets the NS5B RNA-dependent RNA polymerase, a non-structural protein essential for HCV genome replication. By inhibiting this enzyme, the drug prevents the virus from synthesizing new RNA copies, thereby suppressing viral replication and reducing viral load in infected patients.","oneSentence":"ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:26.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT00361881","phase":"PHASE3","title":"Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis","status":"COMPLETED","sponsor":"Medivir","startDate":"2006-07","conditions":"Herpes Labialis","enrollment":1443},{"nctId":"NCT00375570","phase":"PHASE3","title":"Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents","status":"COMPLETED","sponsor":"Medivir","startDate":"2006-10","conditions":"Herpes Labialis","enrollment":254},{"nctId":"NCT00735761","phase":"PHASE3","title":"Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients","status":"COMPLETED","sponsor":"Medivir","startDate":"2006-12","conditions":"Herpes Labialis","enrollment":201},{"nctId":"NCT00736437","phase":"PHASE2","title":"Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis","status":"COMPLETED","sponsor":"Medivir","startDate":"1999-08","conditions":"Herpes Labialis","enrollment":417}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ME-609","genericName":"ME-609","companyName":"Medivir","companyId":"medivir","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}